Bouttefeux Oriane, Beloqui Ana, Preat Veronique
Universite catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73 bte B1 73.12, B-1200 Brussels, Belgium.
Curr Pharm Des. 2016;22(9):1161-76. doi: 10.2174/1381612822666151216150238.
Over the last years, the interest of the pharmaceutical industry in the use of therapeutic peptides in diabetes treatment has been increased. However, these are restricted to parenteral administration. In order to mimic the natural physiological response, many efforts have been made towards oral peptide delivery in diabetes treatment. This review article aims to give an overview on the progress in the nanomedicine field towards the design and optimization of nanoparticle-based drug delivery systems capable of overcoming the harsh gastrointestinal environment and achieving an adequate bioavailability following oral administration. The reported data clearly illustrate the promise of nanomedicine for antidiabetic oral peptide delivery.
在过去几年中,制药行业对治疗性肽在糖尿病治疗中的应用兴趣有所增加。然而,这些肽仅限于肠胃外给药。为了模拟自然生理反应,人们在糖尿病治疗中的口服肽递送方面做出了许多努力。这篇综述文章旨在概述纳米医学领域在设计和优化基于纳米颗粒的药物递送系统方面取得的进展,这些系统能够克服恶劣的胃肠道环境,并在口服给药后实现足够的生物利用度。报道的数据清楚地说明了纳米医学在抗糖尿病口服肽递送方面的前景。